FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016069234> ?p ?o ?g. }

• W2016069234 endingPage "607" @default.
• W2016069234 startingPage "601" @default.
• W2016069234 abstract "Advanced ovarian carcinoma in early progression (<6 months) (AOCEP) is considered resistant to most cytotoxic drugs. Gemcitabine (GE) and oxaliplatin (OXA) have shown single-agent activity in relapsed ovarian cancer. Their combination was tested in patients with AOCEP in phase II study. Fifty patients pre-treated with platinum–taxane received q3w administration of OXA (100 mg m–2, d1) and GE (1000 mg m–2, d1, d8, 100-min infusion). Patient characteristics were a : median age 64 years (range 46–79),and 1 (84%) or 2 (16%) earlier lines of treatment. Haematological toxicity included grade 3–4 neutropaenia (33%), anaemia (8%), and thrombocytopaenia (19%). Febrile neutropaenia occurred in 3%. Non-haematological toxicity included grade 2–3 nausea or vomiting (34%), grade 3 fatigue (25%),and grade 2 alopecia (24%). Eighteen (37%) patients experienced response. Median progression-free (PF) and overall survivals (OS) were 4.6 and 11.4 months, respectively. The OXA–GE combination has high activity and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA–GE with single-agent treatment is warranted." @default.
• W2016069234 created "2016-06-24" @default.
• W2016069234 creator A5004452040 @default.
• W2016069234 creator A5012827037 @default.
• W2016069234 creator A5018378577 @default.
• W2016069234 creator A5022732830 @default.
• W2016069234 creator A5026465346 @default.
• W2016069234 creator A5030957656 @default.
• W2016069234 creator A5032686530 @default.
• W2016069234 creator A5037416771 @default.
• W2016069234 creator A5045861697 @default.
• W2016069234 creator A5050042323 @default.
• W2016069234 creator A5056064173 @default.
• W2016069234 creator A5058001432 @default.
• W2016069234 creator A5061048782 @default.
• W2016069234 creator A5061926237 @default.
• W2016069234 creator A5070962149 @default.
• W2016069234 creator A5073063132 @default.
• W2016069234 creator A5073713547 @default.
• W2016069234 creator A5077775252 @default.
• W2016069234 date "2009-02-01" @default.
• W2016069234 modified "2023-10-17" @default.
• W2016069234 title "Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group" @default.
• W2016069234 cites W1942558153 @default.
• W2016069234 cites W1945760023 @default.
• W2016069234 cites W1960327677 @default.
• W2016069234 cites W1984254136 @default.
• W2016069234 cites W1988305907 @default.
• W2016069234 cites W2006611606 @default.
• W2016069234 cites W2041960461 @default.
• W2016069234 cites W2048266381 @default.
• W2016069234 cites W2084233475 @default.
• W2016069234 cites W2085032784 @default.
• W2016069234 cites W2090859762 @default.
• W2016069234 cites W2130017050 @default.
• W2016069234 cites W2132865716 @default.
• W2016069234 cites W2133506440 @default.
• W2016069234 cites W2139248078 @default.
• W2016069234 cites W2141048775 @default.
• W2016069234 cites W2147808471 @default.
• W2016069234 cites W2149312775 @default.
• W2016069234 cites W2152960203 @default.
• W2016069234 cites W2155126523 @default.
• W2016069234 cites W3028515504 @default.
• W2016069234 cites W4231089745 @default.
• W2016069234 doi "https://doi.org/10.1038/sj.bjc.6604878" @default.
• W2016069234 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2653739" @default.
• W2016069234 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19190632" @default.
• W2016069234 hasPublicationYear "2009" @default.
• W2016069234 type Work @default.
• W2016069234 sameAs 2016069234 @default.
• W2016069234 citedByCount "20" @default.
• W2016069234 countsByYear W20160692342013 @default.
• W2016069234 countsByYear W20160692342014 @default.
• W2016069234 countsByYear W20160692342015 @default.
• W2016069234 countsByYear W20160692342016 @default.
• W2016069234 crossrefType "journal-article" @default.
• W2016069234 hasAuthorship W2016069234A5004452040 @default.
• W2016069234 hasAuthorship W2016069234A5012827037 @default.
• W2016069234 hasAuthorship W2016069234A5018378577 @default.
• W2016069234 hasAuthorship W2016069234A5022732830 @default.
• W2016069234 hasAuthorship W2016069234A5026465346 @default.
• W2016069234 hasAuthorship W2016069234A5030957656 @default.
• W2016069234 hasAuthorship W2016069234A5032686530 @default.
• W2016069234 hasAuthorship W2016069234A5037416771 @default.
• W2016069234 hasAuthorship W2016069234A5045861697 @default.
• W2016069234 hasAuthorship W2016069234A5050042323 @default.
• W2016069234 hasAuthorship W2016069234A5056064173 @default.
• W2016069234 hasAuthorship W2016069234A5058001432 @default.
• W2016069234 hasAuthorship W2016069234A5061048782 @default.
• W2016069234 hasAuthorship W2016069234A5061926237 @default.
• W2016069234 hasAuthorship W2016069234A5070962149 @default.
• W2016069234 hasAuthorship W2016069234A5073063132 @default.
• W2016069234 hasAuthorship W2016069234A5073713547 @default.
• W2016069234 hasAuthorship W2016069234A5077775252 @default.
• W2016069234 hasBestOaLocation W20160692341 @default.
• W2016069234 hasConcept C121608353 @default.
• W2016069234 hasConcept C126322002 @default.
• W2016069234 hasConcept C141071460 @default.
• W2016069234 hasConcept C143998085 @default.
• W2016069234 hasConcept C2776694085 @default.
• W2016069234 hasConcept C2777511904 @default.
• W2016069234 hasConcept C2780258809 @default.
• W2016069234 hasConcept C2780427987 @default.
• W2016069234 hasConcept C2780580376 @default.
• W2016069234 hasConcept C2780852908 @default.
• W2016069234 hasConcept C2780962732 @default.
• W2016069234 hasConcept C29730261 @default.
• W2016069234 hasConcept C31760486 @default.
• W2016069234 hasConcept C526805850 @default.
• W2016069234 hasConcept C530470458 @default.
• W2016069234 hasConcept C71924100 @default.
• W2016069234 hasConcept C90924648 @default.
• W2016069234 hasConceptScore W2016069234C121608353 @default.
• W2016069234 hasConceptScore W2016069234C126322002 @default.
• W2016069234 hasConceptScore W2016069234C141071460 @default.
• W2016069234 hasConceptScore W2016069234C143998085 @default.
• W2016069234 hasConceptScore W2016069234C2776694085 @default.

• next